Lilly climbs, Novo falls as obesity drug battle intensifies
A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Novo vs. Lilly: Q2's cardiometabolic grudge match endpoints.news